All In Biotech

Drug Trial Radar · NCT07489131

Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema

A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared With Eylea HD in Participants With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 256 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

256

Planned (sponsor's estimate)

Start

Apr 22, 2026

Primary completion

Jul 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Alvotech Swiss AGIndustry
Sponsor type
Industry
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea HD in Participants with Diabetic Macular Edema.

Conditions

  • Diabetic Macular Edema

Interventions

  • AVT29 (proposed aflibercept HD biosimilar)Drug

    Patients will receive IVT injections of AVT29

  • Eylea HD (aflibercept HD)Drug

    Patients will receive IVT injections of Eylea HD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to Week 8 in BCVA as measured by ETDRS letter scoreTime frame: week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site 3004

    Budapest, Hungary · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.